证券代码：600252 证券简称：中恒集团 公告编号：临 2023-53 广西梧州中恒集团股份有限公司 关于计提信用减值损失的公告 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、计提资产减值准备情况概述 根据企业会计准则的相关规定，广西梧州中恒集团股份有限公司（以下简称 "公司"或"中恒集团"）基于谨慎原则，于 2023 年半年度末对各项资产进行全 面检查及减值测试，以确保公司财务报表在所有重大方面公允反映公司 2023 年 6 月 30 日财务状况以及 2023 年半年度经营成果和现金流量。2023 年半年度末根 据检查和测试结果计提减值损失合计 14,034,952.05 元，占公司最近一个会计年 度经审计净利润绝对值的比例为 17.76%，具体如下： 单位：元，币种：人民币 | 项目 | 本期计提金额 | | --- | --- | | 一、信用减值损失 | 11,305,601.08 | | 其中：应收票据坏账损失 | -9,738.40 | | 应收账款坏账损失 | 2,351,547.40 | | 其他应 ...

重要内容提示： 广西梧州中恒集团股份有限公司 关于公司拟公开挂牌转让参股公司股权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 ● 为进一步提高公司资产管控效能及使用效率，聚焦主业，广西梧州中恒 集团股份有限公司（以下简称"公司"）现拟通过挂牌方式转让所持广西联合资 产管理股份有限公司（以下简称"联合资管"）的 18%股权。 ● 本次交易对方尚不确定，暂无法确定是否构成关联交易。本次交易不构 成《上市公司重大资产重组管理办法》规定的重大资产重组情形。 ● 本次交易能否征集到受让方和最终交易价格尚存在不确定性，公司将根 据交易进展情况及时履行信息披露义务。 ● 本次交易尚需交易相关方履行审议程序、相关监管部门审批/备案后实施。 交易实施结果存在不确定性，敬请广大投资者谨慎决策，注意投资风险。 一、交易概述 联合资管是公司参股公司，设立于 2016 年 10 月 21 日，注册资本 100,000.00 万元，公司目前持有其 18%股权。为进一步提高公司资产管控效能及使用效率， 聚焦主业，公司拟通过挂牌方式转让所持联合资管 ...

证券代码：600252 证券简称：中恒集团 公告编号：临 2023-51 广西梧州中恒集团股份有限公司（以下简称"公司"或"中恒集团"）第九 届董事会第五十三次会议通知和议案材料于 2023 年 8 月 18 日以电子邮件的方式 发出，会议于 2023 年 8 月 28 日以现场结合通讯方式在广西南宁市江南区高岭路 100 号办公楼会议室召开，会议由公司董事长莫宏胜先生主持；董事李文先生因 工作原因无法出席现场会议，委托董事王海润先生出席并代为表决；独立董事王 洪亮先生因工作原因无法出席现场会议，以通讯方式参加。本次会议应参加表决 董事 9 人，实际参加会议表决董事 9 人。会议的召集和召开符合《公司法》《公 司章程》和《公司董事会议事规则》的有关规定。 二、董事会会议审议情况 会议审议并以记名投票方式表决通过以下议案及事项： 广西梧州中恒集团股份有限公司 第九届董事会第五十三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 （一）会议审议通过《广西梧州中恒集团股份有限公司 2023 年半 ...

证券代码：600252 证券简称：中恒集团 公告编号：临 2023-50 广西梧州中恒集团股份有限公司 关于公司控股子公司及控股孙公司涉及诉讼 的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 案件所处的诉讼阶段：已缴纳上诉费（二审），尚未开庭。 上市公司所处的当事人地位：重庆莱美药业股份有限公司（以下简称"莱 美药业"）及其全资子公司重庆市莱美医药有限公司（以下简称"莱美医药"）为 案件一审的被告、二审的上诉人，莱美药业及莱美医药分别系广西梧州中恒集团 股份有限公司（以下简称"公司"或"中恒集团"）的控股子公司和控股孙公司。 涉案金额：51,457,500 元。 是否会对上市公司损益产生负面影响：根据本次诉讼案件一审判决结果， 基于谨慎性原则，经公司财经部初步测算，预计对公司本年度利润的影响金额为 -51,761,588 元。因本次诉讼案件二审尚未正式开庭审理，二审判决结果尚具有不 确定性，后续公司将结合实际情况按照会计准则的要求进行账务处理，对公司经 营业绩的影响以年度审计确认后的结果为准。 敬请 ...

证券代码：600252 证券简称：中恒集团 公告编号：临 2023-49 广西梧州中恒集团股份有限公司 关于控股孙公司获得政府补助的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 获得补助金额：41,593,315.00 元 ● 对当期损益的影响：本次收到政府补助共 41,593,315.00 元，其中，2022 年计提 29,999,330.93 元，已计入 2022 年度当期损益其他收益科目，2022 年计提 金额与实际收到金额之间的差额 11,593,984.07 元将计入 2023 年度当期损益。 一、获取政府补助的基本情况 广西梧州中恒集团股份有限公司（以下简称"公司"）控股孙公司西藏莱美 德济医药有限公司（以下简称"莱美德济"）依据《拉萨经济技术开发区关于进 一步促进产业高质量发展 1+N 政策的实施意见》的相关规定，于近日收到西藏 拉萨经济技术开发区管理委员会下发的 2022 年度产业发展扶持资金，共计 41,593,315.00 元，占公司最近一年经审计净利润的 52.63%。本次获得 ...

证券代码：600252 证券简称：中恒集团 公告编号：临 2023-41 广西梧州中恒集团股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2023 年 5 月 25 日(星期四)上午 10:00-11:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 5 月 18 日(星期四)至 5 月 24 日(星期三)16:00 前登 录上证路演中心网站首页点击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 （zh600252@126.com）进行提问。广西梧州中恒集团股份有限公司（以下简称 "公司"或"中恒集团"）将在业绩说明会上对投资者普遍关注的问题进行回答。 公司于 2023 年 3 月 29 日披露了《中恒集团 2022 年年度报告》，为便于广大 投资者 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 669,688,145.45, representing a year-on-year increase of 4.56%[3] - The net profit attributable to shareholders was CNY -17,116,845.17, a decrease of 119.94% compared to the same period last year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 1,671,103.18, down 97.78% year-on-year[3] - Basic and diluted earnings per share were both CNY -0.0050, a decline of 120.08% compared to the previous year[3] - The weighted average return on equity was -0.26%, a decrease of 1.55 percentage points[3] - The company reported significant shareholder concentration, with Guangxi Investment Group Co., Ltd. holding 859,343,587 shares, representing a substantial portion of the total shares[9] - In Q1 2023, the company reported a net profit of -29,006,693.77 CNY, a significant decline compared to a net profit of 57,322,111.10 CNY in Q1 2022, representing a year-over-year decrease of approximately 151%[23]. - The total operating profit for Q1 2023 was -31,199,103.23 CNY, compared to an operating profit of 82,321,214.09 CNY in the same period last year, indicating a drastic decline[23]. - The company’s total comprehensive income for Q1 2023 was -61,491,525.83 CNY, compared to -7,628,677.44 CNY in Q1 2022, reflecting a worsening financial position[24]. - Basic and diluted earnings per share for Q1 2023 were both -0.0050 CNY, down from 0.0249 CNY in Q1 2022[24]. - The company reported a significant loss in fair value changes amounting to -41,037,648.21 CNY in Q1 2023, compared to a gain of 7,738,692.49 CNY in Q1 2022[23]. Cash Flow and Assets - The net cash flow from operating activities increased by 241.05% to CNY 77,608,123.07[3] - The increase in cash flow from operating activities was primarily due to increased cash receipts from pharmaceutical agency business and reduced procurement activities[6] - The company's cash flow from operating activities showed a net inflow of 77,608,123.07 CNY in Q1 2023, a recovery from a net outflow of -55,021,780.87 CNY in Q1 2022[25]. - The company's cash and cash equivalents as of March 31, 2023, amounted to ¥3,580,119,678.67, slightly up from ¥3,549,889,659.07 at the end of 2022[19] - The cash and cash equivalents at the end of Q1 2023 stood at 3,528,662,178.67 CNY, an increase from 3,092,014,678.19 CNY at the end of Q1 2022[25]. - Total assets at the end of the reporting period were CNY 11,681,607,709.04, a decrease of 0.60% from the end of the previous year[3] - The total assets of the company as of March 31, 2023, were ¥11,681,607,709.04, a slight decrease from ¥11,751,848,863.82 at the end of 2022[21] - Total liabilities decreased to ¥3,449,266,781.05 in Q1 2023 from ¥3,462,470,550.07 in Q4 2022[20] Operational Changes and Strategies - The company plans to enhance its promotional efforts, which has impacted profitability in the current period[6] - The company announced that its main products, Thrombolytic Injection (Lyophilized) and Thrombolytic Injection, have had restrictions on their indications lifted, restoring their reimbursement scope to the range specified in the product instructions[11] - The company established a wholly-owned subsidiary, Zhongheng Yixin Technology Investment Co., Ltd., with an investment of RMB 500 million to enhance its technological innovation and investment management capabilities[13] - The company plans to repurchase and cancel a total of 12,944,250 restricted stock units due to unmet performance targets from its 2021 incentive plan, with repurchase prices set at RMB 1.76 and RMB 1.42 per share[15] - The company completed the cancellation of 6,373,443 shares remaining in its repurchase special securities account, with no current plans for their use[16] - The company is actively monitoring changes in national medical insurance policies that may impact its product offerings and market positioning[10] - The company has not disclosed any significant mergers or acquisitions in the recent report, focusing instead on internal growth strategies[17] - The company is committed to enhancing its market presence through strategic investments and product development initiatives[13] Cost and Expense Management - Total operating costs for Q1 2023 were ¥683,670,796.28, up 19.6% from ¥571,823,205.03 in Q1 2022[22] - Research and development expenses decreased to ¥25,174,529.19 in Q1 2023 from ¥45,658,550.65 in Q1 2022, indicating a reduction of 44.7%[22] - The net profit margin for Q1 2023 was impacted by increased operating costs, with a total profit of ¥13,869,037.33 from other income, compared to ¥11,689,913.24 in Q1 2022[22] Inventory and Receivables - Accounts receivable increased to ¥873,121,677.50 in Q1 2023 from ¥836,153,269.26 in Q4 2022, indicating a rise of 4.2%[19] - Inventory levels rose to ¥768,615,385.99 in Q1 2023, compared to ¥689,839,512.64 in Q4 2022, reflecting an increase of 11.4%[19]

Financial Performance - In 2022, the company's operating revenue was approximately ¥9.86 million, a decrease of 54.3% compared to ¥21.55 million in 2021[24]. - The company's operating revenue for 2022 was CNY 2,713,769,838.72, a decrease of 14.17% compared to CNY 3,161,843,646.17 in 2021[35]. - Net profit attributable to shareholders for 2022 was CNY 79,025,459.61, down 74.25% from CNY 306,918,694.92 in the previous year[35]. - The net cash flow from operating activities was negative CNY 170,090,446.75, compared to negative CNY 76,736,671.04 in 2021[35]. - The company's total assets at the end of 2022 were CNY 11,751,848,863.82, a decrease of 1.16% from CNY 11,889,723,464.97 at the end of 2021[35]. - The net profit for the year was CNY 12,389,674.15, a significant decrease from CNY 173,166,289.20 in the previous year, representing a decline of approximately 92.85%[108]. - The total comprehensive income for the year was CNY -83,743,394.70, compared to CNY 4,641,377.31 in the previous year, indicating a substantial decline[110]. Research and Development - The company has applied for 26 patents, including 19 invention patents, since its establishment[19]. - The company has established multiple industry-academia-research platforms, including a "Three Seven Research Center" with Shanghai University of Traditional Chinese Medicine[19]. - The company has established several national and regional research centers to enhance its R&D capabilities and core competitiveness[48]. - Laimei Pharmaceutical's R&D investment in 2022 totaled 156 million, a decrease of 27.42% year-on-year, with a capitalization ratio of 13.76%, an increase of 5.51 percentage points from the previous year[142]. - The company is focusing on the development of key products such as Esomeprazole Magnesium and Tranexamic Acid, with a significant increase in the capitalization of R&D expenses by 21.04%[142]. Product Development and Portfolio - Wuzhou Pharmaceutical has 217 product varieties and 308 drug approval numbers, including 181 traditional Chinese medicine products and 118 chemical drug formulations[18]. - Laimei Pharmaceutical's key product, Kanalin, is the first lymph tracer approved by CFDA and has won multiple industry awards, including "Outstanding Product Brand" for four consecutive years[18]. - The company has received approval for two new drug registration certificates from the National Medical Products Administration, enhancing its product portfolio[42]. - The company is focusing on the development of upgraded products such as nano carbon iron and personalized innovative medical technologies through its subsidiaries[157]. Market Strategy and Sales - The company has adopted a dual-market operation strategy, focusing on both hospital and retail markets to drive business growth[20]. - The company has implemented a sales model that combines professional academic promotion with channel distribution, enhancing market penetration[20]. - The company has expanded its online sales channels, with significant growth in sales through the Laimei Juding e-commerce platform compared to the previous period[57]. - The company plans to enhance marketing management and optimize sales channels, focusing on core product promotion capabilities and transforming sales team management[192]. Corporate Governance and Compliance - The company has received a standard unqualified audit report from Yongtuo Accounting Firm[2]. - The company’s board of directors and senior management have guaranteed the authenticity, accuracy, and completeness of the annual report[2]. - The company emphasizes that forward-looking statements in the report do not constitute substantive commitments to investors, highlighting investment risks[2]. - The company aims to strengthen the safety control of pharmaceuticals in response to the revised Drug Administration Law, ensuring compliance with regulations[95]. Investment and Financial Management - The company has ongoing research and development projects, including the injection of thrombolytic agents and various traditional Chinese medicine formulations, with several products in different stages of clinical research and registration[158]. - The total external equity investment during the reporting period was CNY 250,000, a significant decrease of 99.90% compared to CNY 25,000,000 in the previous year, indicating a strategic focus on core business operations[170]. - The company plans to shift its fund management strategy from being limited to outbound investments to also focusing on inbound fundraising, aiming to accelerate the growth of its investment projects[182]. Awards and Recognition - Laimei Pharmaceutical was recognized as a "National Technology Innovation Demonstration Enterprise" in 2019 and has been listed as a key laboratory by Chongqing Economic and Information Commission in 2021[18]. - Shuangqian Industrial has been recognized as a "Demonstration Enterprise of Intelligent Factory" in 2022, highlighting its commitment to modernization and quality[18]. - The company has received multiple awards in the Chinese chemical pharmaceutical industry, highlighting its strong market reputation and product quality[48]. Challenges and Risks - The company faced challenges in the pharmaceutical sector due to government procurement policies, impacting sales volumes across various regions[57]. - The company reported a significant decline in net profit after deducting non-recurring gains and losses, which fell by 92.99% to CNY 5,391,356.31[35]. - The gross profit margin for cardiovascular drugs in 2022 was 86.68%, down from 91.97% in 2021, indicating a decline in profitability[134].

1 证券代码：600252 证券简称：中恒集团 广西梧州中恒集团股份有限公司 投资者关系活动记录表 | --- | --- | |-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关 系活动 | 中恒集团 2021 年度业绩说明会 | | 形式 | □ 现场 √ 网上 □ 电话会议 | | 时间 | 2022 年 5 月 10 日 | | 地点 | 广西梧州 | | 上市公司 接待人员 | 中恒集团党委书记、董事长、代董事会秘书莫宏胜， | | | 常务副总经理钟敏，财务负责人易万伟，独立董事李 俊华。 2022 年 5 月 10 日，中恒集团举办了 2021 年度业 绩说明会。本次业绩说明会 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥700,487,274.79, a decrease of 10.89% compared to the same period last year[6] - The net profit attributable to shareholders for Q3 2022 was ¥37,370,863.73, down 78.71% year-on-year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥3,047,670.21, a decline of 97.04% compared to the previous year[6] - The basic earnings per share for Q3 2022 was ¥0.0109, reflecting a decrease of 78.71% year-on-year[6] - Total operating revenue for the first three quarters of 2022 was CNY 1,890,164,817.86, a decrease of 29.1% compared to CNY 2,668,523,041.62 in the same period of 2021[36] - Net profit for the third quarter of 2022 was CNY 92,292,589.33, a significant decline of 82.4% compared to CNY 523,084,607.27 in the same quarter of 2021[38] - The company reported a total profit of CNY 135,884,567.83 for the third quarter of 2022, down 77.6% from CNY 606,001,644.95 in the same quarter of 2021[38] - The company's investment income for the first three quarters of 2022 was CNY 6,156,884.66, a decline from CNY 99,884,665.37 in the same period of 2021[38] Assets and Liabilities - The total assets at the end of Q3 2022 amounted to ¥11,943,764,621.64, representing a slight increase of 0.45% from the end of the previous year[8] - The equity attributable to shareholders decreased by 1.10% to ¥6,550,695,544.03 compared to the end of the previous year[8] - As of September 30, 2022, the company's total assets amounted to approximately CNY 11.94 billion, an increase from CNY 11.89 billion at the end of 2021[30] - The total liabilities increased to CNY 3.60 billion from CNY 3.20 billion, reflecting an increase of about 12.43%[34] - The company's retained earnings as of September 30, 2022, were CNY 2.44 billion, compared to CNY 2.38 billion at the end of 2021, showing an increase of approximately 2.36%[34] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥11,765,666.46, down 95.04% compared to the same period last year[6] - Cash flow from operating activities for the first three quarters of 2022 was CNY 2,051,996,633.26, a decrease of 28.0% compared to CNY 2,843,611,932.71 in 2021[40] - The net cash flow from operating activities for Q3 2022 was CNY 11,765,666.46, a significant decrease of 95% compared to CNY 237,329,231.85 in Q3 2021[42] - Total cash inflow from financing activities reached CNY 1,794,487,922.04, an increase of 51.3% from CNY 1,185,861,617.70 in the same period last year[44] - The total cash and cash equivalents at the end of Q3 2022 amounted to CNY 3,467,203,227.45, up from CNY 2,896,181,947.52 at the end of Q3 2021[44] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 134,823, with the largest shareholder holding 27.73% of the shares[12] - The company reported a total of 13,523,443 shares held in the repurchase special securities account, accounting for 0.39% of the total share capital as of September 30, 2022[17] - The top ten shareholders include Guangxi Investment Group Co., Ltd. with 963,596,802 shares, representing a significant portion of the company's equity[17] - The top ten unrestricted shareholders include several funds, with the largest being the Central Huijin Asset Management Co., Ltd. holding 49,780,800 shares[17] - The company has not disclosed any known relationships or concerted actions among the top shareholders[17] Management and Governance - The company appointed a new general manager, Ni Yidong, on July 29, 2022, with a term lasting until the end of the current board's tenure[18] - The company also appointed a new board secretary, Wang Xiangyong, on September 29, 2022, effective until the end of the current board's tenure[18] - The company appointed a new deputy general manager, Xiao Lin, on October 18, 2022, with a term until the current board's tenure ends[18] - The company continues to focus on strategic management and governance with recent appointments to enhance operational efficiency[18] - The company revised its 2021 restricted stock incentive plan to enhance its governance structure and motivate key personnel[21] Legal and Regulatory Matters - The decline in net profit was primarily attributed to national pharmaceutical policies and the impact of the pandemic, leading to a decrease in gross profit[11] - The company is facing uncertainties in drug sales due to potential changes in national policies and market conditions, which could affect future revenue[23] - The company’s subsidiary is involved in a legal dispute regarding exclusive sales rights for a product, which may impact its operational focus[25] - The company reported a court ruling requiring it to pay CNY 16.50 million in damages to Haiyue Pharmaceutical, impacting its financial outlook[28] - The company continues to monitor ongoing litigation and will fulfill its disclosure obligations to investors regarding potential risks[28] Product Development - The company received drug registration certificates for 20mg and 40mg Esomeprazole Magnesium enteric-coated capsules, enhancing its product line and market share in gastrointestinal medications[23] - The company’s subsidiary, Chongqing Laimei Pharmaceutical Co., Ltd., obtained approval for the listing application of Esomeprazole Magnesium raw materials, further expanding its product offerings[23] - The company’s subsidiary successfully passed the consistency evaluation for two specifications of Tranexamic Acid Injection, which is expected to improve market competitiveness[23] Operational Activities - The company is in the process of signing an energy-saving service contract for a rooftop photovoltaic project, with a service period of 25 years and a discount of 7.9% on the electricity price[22] - The company is actively pursuing the collection of land reserve compensation amounting to RMB 531.83228 million from the Zhaoqing High-tech Zone Land Reserve Center[24] - The company is closely monitoring the progress of its land compensation claims and is prepared to take necessary actions to protect its interests[24]